AngioDynamics (ANGO) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS
Thursday, July 14, 2021 6:11 PM

AngioDynamics (ANGO) announced its quarterly results on Thursday. The company reported $0.11 earnings per share for the quarter, beating the Thomson Reuters consensus estimate of $0.10 by $0.01. The company’s quarterly revenue was down 6.5% on a year-over-year basis.

On a related note, analysts at Raymond James (NYSE: RJF) downgraded shares of AngioDynamics from an "outperform" rating to a "market perform" rating in a research note to investors on Tuesday, June 14th. Also, analysts at Gabelli downgraded shares of AngioDynamics to a "sell" rating in a research note to investors on Tuesday, June 14th.

Shares of AngioDynamics (ANGO) traded down 2.98% during mid-day trading on Thursday, hitting $14.01. AngioDynamics (ANGO) has a 52 week low of $13.61 and a 52 week high of $17.73. The stock's 50-day moving average is $14.43 and its 200-day moving average is $15.59. The company has a market cap of $349.9 million and a price-to-earnings ratio of 28.31.

AngioDynamics, Inc. (AngioDynamics) is a provider of medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease (PVD) and local oncology therapy options for treating cancer, including radiofrequency ablation (RFA) systems, NanoKnife Ablation Systems, surgical resection systems and embolization products for treating benign and malignant tumors. It designs, develops, manufactures and markets a line of therapeutic and diagnostic devices that enable interventional physicians to treat PVD, tumors, and other non-coronary diseases. The Company operates in three segments: Peripheral Vascular, Access and Oncology/Surgery. The Peripheral Vascular segment consists of its venous, angiographic, percutaneous transluminal angioplasty, drainage and thrombolytic product lines. The Access segment consists of its dialysis, ports and PICC product lines. The Oncology/Surgery segment consists of its RFA, embolization, Habib and NanoKnife product lines.

Stay on top of analysts' coverage with American Banking & Market News' daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day.Click here to register.


 

Sponsors

Advertisement


Advertisement